Compare Amphastar Pharmaceuticals Inc (AMPH) vs Endeavour Silver Corp (EXK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Endeavour Silver Corp — how do they compare? Amphastar Pharmaceuticals Inc trades at $19.35 (market cap $826.08M), while Endeavour Silver Corp trades at $7.93 (market cap $2.39B). The key difference: Endeavour Silver Corp is far larger — about 2.9× Amphastar Pharmaceuticals Inc's market cap, and Endeavour Silver Corp is trading nearer its 52-week high, Amphastar Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| AMPH | EXK | |
|---|---|---|
Market Cap | $826.08M | $2.39B |
Sector | Health | Basic Materials |
52-Week High | $30.81 | $14.12 |
52-Week Low | $16.87 | $4.96 |
Enterprise Value | $1.22B | $2.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Endeavour Silver (EXK) trades at $8.08, down 1.94% with bearish technical signals despite strong Q2 2026 production results. The company shows improving fundamentals with Q1 2026 earnings beating estimates at $0.21 per share versus $0.10 expected, while revenue trends project growth from $468M in 2025 to $614M in 2026. Analyst sentiment remains overwhelmingly positive with 11 buy ratings out of 14 total recommendations.
EXK presents a recovery opportunity as silver prices strengthen and production expands, though negative net margins and high valuation ratios pose near-term risks. The expiration of silver collars in June 2026 could unlock significant cash flow, providing catalysts for upside potential despite current technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Endeavour Silver Corp
Endeavour Silver is a mid-tier precious metals mining company. It operates silver-gold mines in Mexico and is focused on growing its production and reserves through exploration and the development of new mining projects.
Read more on EXK →
